Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$13.1MCash on Hand
14.5mo Cash Runway
Follow BLRX by emailGet an email when BLRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BLRX, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Clinical trial Two SNO 2026 posters on GLIX1 were presented, with a fourth cohort now dosed in the Phase 1/2a study and no significant treatment-emergent adverse events observed. Results are expected in the first half of next year, and window-of-opportunity cohorts will assess brain penetration. Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Clinical trial Presented preclinical ESMO 2026 data showing GLIX1 synergy with PARP inhibitors olaparib, veliparib and niraparib in HR-proficient ovarian cancer cell lines, with ZIP synergy scores of 10.9 to 43.2. Form 6-K · SEC filing · Press release
Oct 2, 2026 ·
Financing Prospectus for resale of up to 2,023,382 ADSs issuable on exercise of warrants from the August 2026 private placement, priced at $2.78 per ADS. The company receives no proceeds from resales, but may receive cash on warrant exercise. Form 424B3 · SEC filing
Sep 25, 2026 ·
Financing BioLineRx registered resale of up to 2,023,382 ADSs issuable on exercise of warrants from an August 2026 private placement. The company receives no proceeds from resales, only any cash from warrant exercises. ADSs closed at $2.56 on Sept 23, 2026. Form F-1 · SEC filing
Sep 24, 2026 ·
Shareholder vote Shareholders approved all five proposals at the September 23, 2026 annual general meeting, including re-electing three Class III directors, increasing authorized share capital, equity grants to CEO Philip Serlin and certain directors, and reappointing Kesselman & Kesselman as auditor. Form 6-K · SEC filing
Sep 10, 2026 ·
BioLineRx and Hemispherian will present GLIX1 preclinical glioblastoma data as a mini-oral and a Phase 1/2a trial design e-poster at EANO 2026 in Rome on September 24-27. The Phase 1/2a trial (NCT07464925) is actively enrolling patients. Form 6-K · SEC filing · Press release
Aug 31, 2026 ·
Financing Reported Q2 2026 results with $13.1 million in cash as of June 30, 2026, maintaining cash runway into the first half of 2027. Q2 net loss was $4.3 million and R&D expenses rose to $2.9 million, driven by the GLIX1 project. Form 6-K · SEC filing · Press release
Aug 31, 2026 ·
Financing Entered a registered direct offering and concurrent private placement of ADSs and warrants, with expected gross proceeds of about $3,750,000 before fees, priced at $2.78 per ADS and accompanying warrant. Net proceeds are for R&D and working capital. Closing expected August 31, 2026. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Sep 2022 · Phase 2 · Results Expected · Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients Registry primary completion date, not a results date
Jun 2022 · Phase 1 · Results Expected · Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects Registry primary completion date, not a results date
Dec 2020 · Phase 3 · Active Trial · A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of… Registry primary completion date, not a results date
Nov 2020 · Phase 2 · Results Expected · Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic… Registry primary completion date, not a results date
Mar 2016 · Phase 2 · Results Expected · Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients Registry primary completion date, not a results date
Jul 2015 · Phase 1 · Results Expected · A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not BLRX's own candidates): Risperidone, Paclitaxel, Leucovorin, Oxaliplatin, Pembrolizumab, Ramucirumab, Ribavirin, Atezolizumab, Cyclosporine, Cisplatin, Cobimetinib, Perphenazine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BLRX holds $13.1M in cash and short-term investments and burns about $2.7M/quarter from operations,
an estimated runway of 14.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:22 · Moderate
Cash runway not available
ATM program on file since Jul 2025 +15
Shelf registration (F-3, Dec 2023) +10
Share count +17% in a year +7
Raised after last reported balance sheet (Aug 2026) -10
Recent financing filings on SEC EDGAR:
Aug 31, 2026 · Registered direct / best-efforts offering · 424B5
Share count 2,610,814,390 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BLRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BLRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.